DrugBiological
Iscalimab clinical trials
Also written CFZ533.
- studies test it
- 12
- open now
- 0
- in phase 3
- 0
- first study started
- 2013
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2019 (4)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 2 |
| 2019 | 4 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 11
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 0
Often tested with
Tested in the same studies.
Ianalumab (2) · LYS-006 (1) · Arumakimig (1) · Remibrutinib (1) · Tacrolimus (1)
Studies
Open first, then newest update. How each study uses iscalimab is read from its arms, and is right about nine times in ten.
Testing it · 12
- Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis SuppurativaCompletedPhase 2Novartis PharmaceuticalsNCT03827798Written as CFZ533
- Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's SyndromeCompletedPhase 2Novartis PharmaceuticalsNCT03905525Written as CFZ533
- Study the Efficacy and Safety of VAY736 and CFZ533 in SLE PatientsCompletedPhase 2Novartis PharmaceuticalsNCT03656562Written as CFZ533
- Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's SyndromeCompletedPhase 2Novartis PharmaceuticalsNCT04541589Written as Iscalimab
- Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term ExtensionTerminatedPhase 2Novartis PharmaceuticalsNCT03781414Written as CFZ533
- Study of Safety and Efficacy of CFZ533 in Type 1 Diabetes Pediatric and Young Adult SubjectsCompletedPhase 2Novartis PharmaceuticalsNCT04129528Written as CFZ533
- Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis.CompletedPhase 2Novartis PharmaceuticalsNCT03610516Written as CFZ533
- CCFZ533X2201 - PoC Study in de Novo Renal TransplantationCompletedPhase 1/2Novartis PharmaceuticalsNCT02217410Written as CFZ533
- Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's SyndromeCompletedPhase 2Novartis PharmaceuticalsNCT02291029Written as CFZ533 active - Cohort 1
- Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia GravisCompletedPhase 2Novartis PharmaceuticalsNCT02565576Written as CFZ533
- A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' DiseaseCompletedPhase 2Novartis PharmaceuticalsNCT02713256Written as CFZ533
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis PatientsCompletedPhase 1Novartis PharmaceuticalsNCT02089087Written as CFZ533
Codes
What other systems call iscalimab · ClinicalTrials.gg INT000887
- MeSH (NLM) C000626035iscalimabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 0628T707D0ISCALIMABConfirmed FDA, NLM
- NCI Thesaurus C175096IscalimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000626035 | iscalimab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 0628T707D0 | ISCALIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C175096 | Iscalimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.